Video

October 27, 2014

Dr Steven Nathan Discusses the 2 Newly Approved Drugs to Treat IPF

The big news at the 2014 CHEST meeting in Austin, TX, was that 2 new drugs - pirfenidone and nintedanib - were approved to treat idiopathic pulmonary fibrosis, according to Steven Nathan, MD, medical director of the Lung Transplant Program at Inova Fairfax Hospital in Falls Church, VA.

The big news at the 2014 CHEST meeting in Austin, TX, was that 2 new drugs—pirfenidone and nintedanib—were approved to treat idiopathic pulmonary fibrosis (IPF), according to Steven Nathan, MD, medical director of the Lung Transplant Program at Inova Fairfax Hospital in Falls Church, VA.

Prior to these 2 drugs, which both slow the rate of decline of lung function, nothing had been approved to treat this fatal lung disease.

“[IPF] has a median survival of anywhere from 2-and-a-half to 5 years,” Dr Nathan explained. “So there’s been a lack of medical therapies for these conditions. So both of them offer some hope to patients with this condition.”

Related Videos

H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview

Samir Shah, MD, MMM, FACR

Dr Brian Slomovitz

Reynold Panettieri, Jr, MD

Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre

Jill Feldman, patient, cofounder and president, EGFR Resisters

Reynold Panettieri, Jr, MD

Danny Rischin, MD, medical oncologist, clinician researcher, Peter McCallum Cancer Centre

James Chalmers, MD

Related Content

Anjali Vaidya, MD, FACC, FASE, FACP | Image Credit: Temple University Hospital

June 4th 2025

New Insights Into Meth-Associated PAH Care Gaps: Insights From Anjali Vaidya, MD

Maggie L. Shaw Anjali Vaidya, MD, FACC, FASE, FACP

Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL

June 3rd 2025

In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.

Managed Care Cast.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

Saad Z. Usmani, MD, MBA | Image credit: MSKCC

June 2nd 2025

Depth of Responses, PFS in Transplant-Ineligible Patients Match Overall Findings in CEPHEUS

Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.

Data suggest trastuzumab deruxtecan and pertuzumab may represent a new first-line standard of care for metastatic, HER2-positive breast cancer. | Image credit: Axel Kock - stock.adobe.com

June 2nd 2025

Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.

Related Content

Anjali Vaidya, MD, FACC, FASE, FACP | Image Credit: Temple University Hospital

June 4th 2025

New Insights Into Meth-Associated PAH Care Gaps: Insights From Anjali Vaidya, MD

Maggie L. Shaw Anjali Vaidya, MD, FACC, FASE, FACP

Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL

June 3rd 2025

In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.

Managed Care Cast.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

Saad Z. Usmani, MD, MBA | Image credit: MSKCC

June 2nd 2025

Depth of Responses, PFS in Transplant-Ineligible Patients Match Overall Findings in CEPHEUS

Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.

Data suggest trastuzumab deruxtecan and pertuzumab may represent a new first-line standard of care for metastatic, HER2-positive breast cancer. | Image credit: Axel Kock - stock.adobe.com

June 2nd 2025

Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions